MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
June 9, 2011
Brian Orelli
It's a Numbers Game With Vertex In the longer term, the number of patients Vertex can address with its cystic fibrosis drugs will play a major role in its valuation. mark for My Articles similar articles
The Motley Fool
March 28, 2008
Brian Lawler
Vertex Tantalizes Us With Very Early Data Vertex announces positive early-stage data for a cystic fibrosis drug. mark for My Articles similar articles
The Motley Fool
January 3, 2011
Travis Hoium
Inspire Pharmaceuticals Shares Plunged: What You Need to Know The new trading year came in with a loud thud for Inspire Pharmaceuticals when its stock fell 58% this morning. mark for My Articles similar articles
The Motley Fool
October 28, 2011
Brian Orelli
Invest in Biotechs Going After Unmet Needs What a quarter it was for Vertex Pharmaceuticals: $420 million in net sales of its new hepatitis C drug. mark for My Articles similar articles
The Motley Fool
August 11, 2010
Brian Orelli
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. mark for My Articles similar articles
The Motley Fool
April 25, 2008
Brian Lawler
Vertex Silences the Critics New clinical study data bodes well for Vertex Pharmaceuticals' lead drug. mark for My Articles similar articles
The Motley Fool
November 6, 2007
Brian Lawler
No Surprise That Vertex Has Competition Did shares of Vertex Pharmaceuticals slump on competition concerns? mark for My Articles similar articles
The Motley Fool
January 24, 2008
Brian Lawler
Vertex Under the Gun Vertex announces development plans for its lead drug. Investors, take note. mark for My Articles similar articles
The Motley Fool
January 3, 2011
Brian Orelli
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. mark for My Articles similar articles
The Motley Fool
July 25, 2007
Brian Lawler
Vertex Is on Its Way Vertex Pharmaceuticals is still years away from any regulatory approval on telaprevir in the U.S., but highlights promising results so far in its quarterly report. mark for My Articles similar articles
The Motley Fool
April 23, 2008
Brian Lawler
Vertex Verging on Crucial News Soon-to-arrive study results could decide the future of Vertex Pharmaceutical's lead drug telaprevir. mark for My Articles similar articles
Chemistry World
June 9, 2015
Phillip Broadwith
Vertex nabs rights to cystic fibrosis molecules Specialist pharmaceutical firm Vertex has struck a development deal with start-up Parion Sciences to develop Parion's investigational drug candidates for respiratory diseases, including cystic fibrosis. mark for My Articles similar articles
The Motley Fool
March 20, 2009
Brian Orelli
EU to Gilead: More Trials for You The U.S. isn't ready for Gilead Sciences' new cystic fibrosis drug, and neither is Europe. mark for My Articles similar articles
The Motley Fool
June 13, 2007
Brian Lawler
Tracking Vertex The pharmaceutical updates investors on the progress of its lead compound. mark for My Articles similar articles
The Motley Fool
October 31, 2011
Brian Orelli
5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon... mark for My Articles similar articles
The Motley Fool
July 27, 2011
Brian Orelli
Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication. mark for My Articles similar articles
The Motley Fool
January 28, 2008
Brian Lawler
Vertex Has a Lot to Prove Vertex Pharmaceuticals announces that final results from its upcoming phase 3 trials wouldn't be ready until the middle of 2010, a far cry from the filing in 2008 that Vertex was previously forecasting. mark for My Articles similar articles
The Motley Fool
December 14, 2006
Brian Lawler
Vertex: Coming Together Nicely If telaprevir continues to show anything like the 80%-90% rate of undetectable hepatitis C virus at end of its trials, Vertex shareholders won't be dealing with too many more down days. mark for My Articles similar articles
The Motley Fool
January 30, 2009
Brian Orelli
Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients. mark for My Articles similar articles
The Motley Fool
April 1, 2008
Brian Lawler
Vertex Proves It ... Almost Vertex announces exciting clinical trial data that could get its anti-hepatitis C virus compound onto the market years earlier. mark for My Articles similar articles
The Motley Fool
September 8, 2010
Brian Orelli
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. mark for My Articles similar articles
The Motley Fool
May 17, 2010
Luke Timmerman
Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir. mark for My Articles similar articles
The Motley Fool
September 6, 2011
Brian Orelli
Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game? mark for My Articles similar articles
The Motley Fool
March 31, 2011
Brian Orelli
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? mark for My Articles similar articles
The Motley Fool
April 27, 2005
Charly Travers
Vertex's Emerging Pipeline Early-stage drugs, including one for hepatitis C, are moving forward. For Vertex investors, the phase 2 trials will be the story to watch over the next two years. mark for My Articles similar articles
The Motley Fool
September 7, 2010
Luke Timmerman
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. mark for My Articles similar articles
The Motley Fool
March 30, 2009
Brian Orelli
Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore. mark for My Articles similar articles
The Motley Fool
April 25, 2011
Luke Timmerman
Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it? mark for My Articles similar articles
The Motley Fool
October 30, 2006
Brian Lawler
Vertex's Healthy Trial Results Shares of the pharmaceutical company were up on the release of positive clinical trial data. mark for My Articles similar articles
The Motley Fool
November 25, 2011
Brian Orelli
7 Black Friday Biotech Bargains Get in at the right time to maximize your returns. mark for My Articles similar articles
The Motley Fool
May 23, 2008
Brian Lawler
Vertex's Lead Cut Down Schering-Plough is moving forward with its antiviral hepatitis C drug even faster than expected, much to Vertex's dismay. mark for My Articles similar articles
The Motley Fool
July 27, 2011
Alexander Crawford
Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve? mark for My Articles similar articles
The Motley Fool
August 4, 2010
Brian Orelli
No Nail Yet, but Vertex Creeps Up to Merck's Coffin Merck's hepatitis C data doesn't look as good as Vertex's. mark for My Articles similar articles
The Motley Fool
January 19, 2012
Brian Orelli
New Hep C Data Impressive, but It's Not There Yet All-oral treatment still has a ways to go. mark for My Articles similar articles
The Motley Fool
February 24, 2011
Brian Orelli
Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead. mark for My Articles similar articles
The Motley Fool
October 31, 2011
Brian Orelli
When Getting Beat Down Is No Big Deal Merck is getting smacked down by Vertex Pharmaceuticals in the hepatitis C market, but it has the bulk to take a beating. mark for My Articles similar articles
American Journal of Nursing
August 2010
Lomas & Fowler
Parents and Children with Cystic Fibrosis A survey was conducted to estimate how many adult patients with cystic fibrosis who receive care at centers accredited by the Cystic Fibrosis Foundation also have biological children with the disease. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2011
Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition. mark for My Articles similar articles
The Motley Fool
March 17, 2008
Brian Orelli
Drugmakers That Make Rivals Green with Envy A look at some drugmakers with cash to spend: Pfizer...Wyeth... Novartis... Amylin Pharmaceuticals... Elan...Vertex Pharmaceuticals... Exelixis... mark for My Articles similar articles
The Motley Fool
December 15, 2011
Luke Timmerman
Vertex Names Jeff Leiden As New CEO, Staring Down Tough New Competition What does new leadership mean for Vertex's future? mark for My Articles similar articles
The Motley Fool
September 26, 2008
Brian Lawler
Less Is More for Vertex The company's potential hepatitis C compound proves effective with fewer dosages. mark for My Articles similar articles
The Motley Fool
August 4, 2010
Ryan McBride
How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals. mark for My Articles similar articles
The Motley Fool
March 27, 2007
Fast Pitch: Vertex Pharmaceuticals 2007 is expected to be a very eventful year for the pharmaceutical, as it will furnish some important clinical trial results for its investigational drugs. Investors, take note. mark for My Articles similar articles
The Motley Fool
August 29, 2011
Anders Bylund
Idenix Pharmaceuticals' Shares Popped: What You Need to Know Shares of viral-disease medication developer Idenix Pharmaceuticals climbed 10.9% on vanishingly thin trading volume. mark for My Articles similar articles
The Motley Fool
April 6, 2011
Brian Orelli
Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire. mark for My Articles similar articles
The Motley Fool
August 4, 2008
Brian Lawler
Vertex on the Verge of Victory Like the majority of biotech drugmakers, Vertex's financials proved less crucial in the second quarter than the clinical trial results from the drugmaker's pipeline. mark for My Articles similar articles
The Motley Fool
August 10, 2010
Ryan McBride
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. mark for My Articles similar articles
Chemistry World
July 31, 2012
Andrew Turley
New cystic fibrosis drug in EU Ivacaftor, which is marketed under the brand name Kalydeco, won US approval in January. mark for My Articles similar articles
The Motley Fool
February 10, 2005
Charly Travers
Focus on the Pipeline Vertex Pharmaceuticals is losing money. But it has at least one drug that makes the future look brighter. mark for My Articles similar articles
The Motley Fool
July 29, 2011
Brian Orelli
Vroom! There Goes Vertex Vertex Pharmaceuticals' Incivek launch is off to a good start. mark for My Articles similar articles